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ABSTRACT
The aim of this study was to synthesize a series of ethylene glycol (EG) ethers and quinoline hybrids of the antimalarial drug
artemisinin and to evaluate their antimalarial activity in vitro against Plasmodium falciparum strains. The ethers were synthesized
in a one-step process by coupling ethylene glycol (EG) moieties of various chain lengths to carbon 10 of dihydroartemisinin, while
the artemisinin-quinoline hybrids were obtained by condensation of dihydroartemisinin with different amine-functionalized
quinoline moieties. For solubility reasons, part of the hybrids were converted to oxalate salts upon reaction of the free bases with
oxalic acid. All the synthesized compounds were tested against chloroquine (CQ) susceptible (CQS) D10 and chloroquine
resistant (CQR) Dd2 Plasmodium falciparum strains. The IC50 values revealed that all the ethers were active against both strains
but less potent than artemether irrespective of the strain. However, they were more active than CQ against the resistant strain.
Ether 8 featuring three EO units was the most active of all ethers. It showed activity similar to that of CQ against D10 and much
more potency than CQ against Dd2 strain (IC50, 0.023 vs. 0.473 nM). The hybrids and their salts were also all active against both
strains. Hybrid 19 which possessed an isopropyl linker and its oxalate salt 19a were the most active against the Dd2 strain. They
were more potent than CQ (IC50, 0.009 and 0.011 vs. 0.255 nM, respectively).
KEYWORDS
Artemisinin (ART), dihydroartemisinin (DHA), artemether (ARM), chloroquine (CQ), malaria, Plasmodium falciparum, ethylene
glycol) (EG), ethylene oxide (EO), hybrid.
1. Introduction
Malaria remains a major cause of morbidity and death in tropical
countries all over the world and a substantial number of people
are exposed to the risk of contracting this deadly disease each
year. With approximately 243 million cases and 863 000 attrib-
uted deaths reported globally in 2009, malaria is one of the most
severe infectious diseases, primarily affecting the world’s most
disadvantaged populations1.
Malaria chemotherapy based on standard drugs such as
quinine especially is becoming more and more difficult because
the malaria parasites, Plasmodium falciparum, causing the disease
have developed widespread resistance against them. This
warrants the search for a new classes of natural and synthetic
antimalarial drugs.
Artemisinin and its derivatives (Fig. 1) showed a rapid onset of
action, low toxicity and high antimalarial activity against both
drug-resistant and drug-sensitive malaria, in early clinical
studies2. The practical values of these antimalarial agents, never-
theless, are impaired by their poor solubility in oil and water,
poor oral bioavailability, high rate of parasite recrudescence
after treatment3 and short plasma half-life4.
In order to overcome these pharmacokinetic deficiencies, a
program aiming at modifying the chemical structure of
artemisinin was launched in 1976, which resulted in a number of
new analogues with improved efficacy and increased solubility:
oil-soluble artemether and arteether 5 and water-soluble sodium
artesunate5. Artemether is the methyl ether derivative of
artemisinin and arteether the ethyl ether derivative; these
compounds are lipophilic and more potent than artemisinin, but
still have a short plasma half-life. Artemisinin, dihydro-
artemisinin 1, artemether and arteether are all poorly water-
soluble compounds, which results in slower and incomplete
absorption of these drugs into the systemic circulation; sodium
artesunate is much more hydrophilic which leads to better
absorption6. However, the usefulness of sodium artesunate in
the treatment of cerebral malaria and multidrug-resistant
P. falciparum is offset by problems associated with its instability in
aqueous medium7, the high rate of recrudescence and the drug’s
extremely short plasma half-life8.
The field for discovering new antimalarial compounds is still
widely open. Gamo and coworkers9 screened nearly 2 million
compounds from GlaxoSmithKline’s chemical library for activity
against P. falciparum and found 13 533 that inhibit para-
site growth by at least 80 % at 2 nM concentration. More than
8000 also showed potent activity against the multidrug resistant
strain Dd2. They are of the opinion that these thousands of
chemicals could be starting points for antimalarial lead identifi-
cation.
Pegylation, generally described as the molecular attachment of
poly(ethylene glycol)s (PEG) with different molecular weights
to active drug molecules, is one of the most promising and exten-
sively studied strategies with the goal of improving the
pharmacokinetic behaviour of therapeutic drugs10. The main
pharmacokinetic outcomes of pegylation are summarized as
changes occurring in overall circulation life-span, tissue distri-
bution pattern, and elimination pathway of the parent drug11.
The attachment of a PEG moiety to drug molecules increases the
RESEARCH ARTICLE D.D. N’Da and J.C. Breytenbach, 163
S. Afr. J. Chem., 2011, 64, 163–172,
<http://journals.sabinet.co.za/sajchem/>.
* To whom correspondence should be addressed. E-mail: david.nda@nwu.ac.za
overall size of the parent drug and the circulation half-life of
PEGs increase with the increase in molecular weight12. Pegylated
drugs are also more stable over a range of pH and temperature
changes13 compared with their unpegylated counterparts. Con-
sequently, pegylation confers on drugs a number of properties
that are likely to result in a number of clinical benefits, including
sustained blood levels that enhance effectiveness, fewer adverse
reactions, longer shelf-life and improved patient convenience14.
In search for stable, more water-soluble, highly potent, long
acting artemisinin derivatives, we modified the artemisinin
molecule by introducing EG moieties at its C10-position through
ether linkage. Furthermore, an emerging strategy within medic-
inal chemistry and drug discovery is the chemical combination
of two distinct pharmacophores into a single molecule, the
so-called hybrid. The hybrid molecule offers a simpler and more
effective way of delivering two drugs, especially when differ-
ences like elimination times occur. A careful choice of the linker
can allow the intact hybrid to dissociate into its individual
components or to remain fixed when metabolically resistant
linker units are chosen. The first case is particularly advanta-
geous if the individual components have different sites of action
within the cell. In the second case, especially with respect to
overcoming resistance, it is desirable for the hybrid to resist
metabolic cleavage15.
The success of quinoline-based antimalarials were based on
their excellent clinical efficacy, limited host toxicity and further
so on. However, their use has been seriously eroded in recent
years, mainly as a result of the development and spread of
parasite resistance16. Despite this, identification of hybrid
4-aminoquinolines having multiple targets is a hope of generat-
ing effective antimalarial chemotherapy17.
Building on this information, we synthesized artemisinin-
quinoline hybrids and evaluated their antiplasmodial activity in
similar conditions as for the EG ethers of artemisinin.




Thin-layer chromatography (TLC) was performed using
silica gel plates (60F254 Merck). Preparative flash column chroma-
tography was carried out on silica gel (230–240 mesh,
G60 Merck) and silica gel 60 (70–230 mesh ASTM, Fluka).
The 1H and 13C NMR spectra were recorded on a Bruker
Avance III 600 spectrometer in deuterated chloroform (CDCl3)
using tetramethylsilane (TMS) as internal standard. The splitting
pattern abbreviations are as follows: s (singlet), d (doublet), dd
(doublet of doublets), Ç (doublet of doublet of doublets), dt
(doublet of triplets), t (triplet), td (triplet of doublets), tt (triplet of
triplet) and m (multiplet).
The low-resolution fast atom bombardment (FAB) mass spec-
tra (MS) were recorded for the artemisinin–EG ethers on a
VG70SE mass spectrometer purchased from Thermo Fisher
Scientific Inc. (Waltam, MA, USA), and using a xenon atom beam
at 8 kV and a 3-nba matrix in all cases. Positive ions (MH+) and
(MNa+) were recorded.
The artemisinin-quinoline hybrids were run on the Thermo
Finnigan (California, US) LXQ linear ion trap using APCI as
ionization mode in positive mode with Vaporizer temp of 340 °C,
capillary temperature of 180 °C and discharge Current at 10 uA.
2.2. Synthetic Procedures
2.2.1. Synthesis of EG Ethers of Artemisinin 3–8
The synthesis of EG ethers of artemisinin (Scheme 1) was
achieved by using with slight modifications the general method
reported by Li et al.18, and described as follows: to a solution
of DHA (1) (2.0 g, 7 mmol) and methoxy(ethylene glycol) (MEG)
or ethoxy(ethylene glycol) (EEG) (14 mmol, 2.0 eq. relative
to DHA) dissolved in 50 mL of anhydrous dichloromethane
(DCM, CH2Cl2), was added boron trifluoride diethyl etherate
(BF3 Et2O) (1.0 mL) portion wise at 0 °C. The mixture was stirred
at 0 °C for 0.5 h, then at room temperature (RT) for 10 h. The
progress of the reaction was monitored by thin layer chromatog-
raphy (TLC). After completion, the reaction mixture was washed
successively with a saturated NaHCO3 solution, water and
brine. The organic layer was dried over MgSO4 and evaporated
to dryness under reduced pressure. The resultant oil was purified
by flash chromatography eluting with DCM:EtOAc (ratios as
described below) as mobile phase. All the synthesized com-
pounds were oils, and failed to crystallize. 1H and 13C NMR
chemical shifts as well as FAB-MS data of compounds 3–8 are
reported.
10Ä-(2-Methoxyethoxy)-dihydroartemisinin 3 (R = CH3, n = 1)
Ether 3 as obtained as clear oil in 38 % yield after purification by
flash silica gel column chromatography eluting with
DCM:EtOAc (20:1). ÇH (600 MHz, CDCl3): 5.41 (1H, s, H-12), 4.80
(1H, d, J 4.8 Hz, H-10), 3.95–3.87 (1H, m, H-18a), 3.58–3.46 (3H, m,
H-18b and H-19), 3.37–3.31 (3H, m, OCH3, H-21), 2.64–2.54 (1H,
m, H-8a), 2.34 (1H, m, H-9), 2.00 (1H, m, H-5a), 1.88–1.57 (5H, m,
H-5, -6 and H-8), 1.51–1.38 (4H, m, H-4 and H-7), 1.35–1.15 (3H,
m, H-14) and ppm 0.95–0.82 (6H, m, H-15 and H-16); ÇC
(600 MHz, CDCl3): 103.04 (C-10), 102.89 (C-3), 88.98 (C-12), 81.60
(C-12a), 71.64 (C-19), 67.53 (C-18), 58.94 (C-21), 51.83 (C-5a), 46.52
(C-8a), 39.45 (C-9), 37.16 (C-4), 36.59 (C-7), 34.47 (C-6), 31.48
(C-14), 25.99 (C-5), 24.64 (C-8), 20.11 (C-15) and ppm 19.46 (C-16);
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Figure 1 Artemisinin and its derivatives.
C18H30O6 (Mw 342.43, calc.); FAB m/z: 343.3 (MH+, 8 %), 365.4
(MNa+, 4 %).
10Ä-[2-(2-Methoxyethoxy) ethoxy]-dihydroartemisinin 4 (R = CH3,
n = 2)
Derivative 4 was purified by flash silica column chromatogra-
phy eluting with DCM:EtOAc (15:1) to produce light yellow oil:
1.28 g (47 %) yield. ÇH (600 MHz, CDCl3): 5.41 (1H, s, H-12), 4.80
(1H, d, J 2.4 Hz, H-10), 3.95–3.87 (1H, m, H-18a), 3.58–3.46 (7H, m,
H-18b, -19, -21 and H-22), 3.37–3.31 (3H, s, OCH3, H-24), 2.64–2.54
(1H, m, H-8a), 2.34 (1H, dd, J 2.4 and14.2 Hz, H-9), 2.00 (1H, d,
J 14.4 Hz, H-5a), 1.88–1.57 (5H, m, H-5, -6 and H -8), 1.51–1.38 (4H,
m, H-4 and H-7), 1.35–1.15 (3H, m, H-14) and ppm 0.95–0.82 (6H,
m, H-15 and H-16); ÇC (600 MHz, CDCl3): 104.10 (C-10), 101.99
(C-3), 87.91 (C-12), 81.13 (C-12a), 71.95 (C-22), 70.52 (C-19), 70.40
(C-21), 67.39 (C-18), 59.03 (C-24), 52.60 (C-5a), 44.41 (C-8a), 37.36
(C-9), 36.40 (C-4), 34.60 (C-7), 30.82 (C-6), 26.16 (C-14), 24.66 (C-5),
24.48 (C-8), 20.25 (C-15) and ppm 12.87 (C-16); C20H34O7 (Mw
386.48, calc.); FAB m/z: 387.3 (MH+, 12 %), 409.3 (MNa+, 11 %).
10Ä-{2-[2-(2-Methoxyethoxy)ethoxy]ethoxy}-dihydroartemisinin 5a
(R = CH3, n = 3)
Purification by silica gel flash chromatography eluting with
DCM:EtOAc (10:1) afforded Ether 5a as yellowish oil in 48 %
yield. ÇH (600 MHz, CDCl3): 5.36 (1H, s, H-12), 4.76 (1H, d, J 4.3 Hz,
H-10), 3.91–3.82 (1H, m, H-18a), 3.62–3.48 (11H, m, H-18b, -19,
-21, -22, -24 and H-25), 3.31 (3H, s, H-27), 2.64–2.55 (1H, m, H-8a),
2.29 (1H, dd, J 4.3 and 14.1 Hz, H-9), 1.96 (1H, d, J 14.4 Hz, H-5a),
1.83–1.65 (4H, m, H-6 and H-8), 1.55 (2H, d, J 12.9, H-5), 1.43–1.34
(4H, m, H-4 and H-7), 1.29–1.11 (3H, m, H-14) and ppm 0.86 (6H,
dd, J 6.8 and 23.3 Hz, H-15 and H-16); Çc (600 MHz, CDCl3): 103.96
(C-10), 102.05 (C-3), 87.90 (C-12), 81.12 (C-12a), 71.92 (C-25), 70.68
(C-19), 70.54 (C-21), 70.50 (C-22), 70.25 (C-24), 67.39 (C-18), 58.94
(C-27), 52.60 (C-5a), 44.41 (C-8a), 37.32 (C-9), 36.40 (C-4), 34.61
(C-7), 30.84 (C-6), 26.16 (C-14), 24.66 (C-5), 24.47 (C-8), 20.41
(C-15) and ppm 12.87 (C-16); C22H38O8 (Mw 430.58, calc.); FAB m/z:
431.4 (MH+, 5 %), 453.4 (MNa+, 25 %).
10~-{2-[2-(2-Methoxyethoxy)ethoxy] ethoxy}-dihydroartemisinin 5b
(R = CH3, n = 3)
Ether 5b was obtained as yellow oil 12 % yield after purification
on flash silica gel eluting with DCM:EtOAc (10:1). ÇH (600 MHz,
CDCl3): 5.26 (1H, s, H-12), 4.44 (1H, d, J 9.2 Hz, H-10), 3.97 (1H, t,
J 8.7 Hz, H-18a), 3.59 (9H, dd, J 6.2 and 16.2 Hz, H-18b, -19, -21, -22
and H-24), 3.49–3.46 (m, 2H, H-25), 3.31 (3H, s, H-27), 2.32 (1H, Ç,
J 5.0, 13.5 and 16.7 Hz, H-8a), 1.95 (1H, d, J 9.2 Hz, H-9), 1.80 (1H,
d, J 13.6 Hz, H-5a), 1.68–1.61 (4H, m, H-6 and H-8), 1.61 (1H, d,
J 13.1 Hz, H-5), 1.50–1.35 (4H, m, H-4 and H-7), 1.27–1.17 (3H, m,
H-14) and ppm 0.95–0.81 (6H, m, H-15 and H-16); ÇC (600 MHz,
CDCl3): 104.22 (C-10), 100.31 (C-3), 91.10 (C-12), 80.40 (C-12a),
71.90 (C-25), 70.86 (C-19), 70.71 (C-21), 70.57 (C-22), 70.42 (C-24),
68.13 (C-18), 58.93 (C-27), 51.53 (C-5a), 45.34 (C-8a), 37.32 (C-9),
36.28 (C-4), 34.28 (C-7), 32.49 (C-6), 26.01 (C-14), 24.67 (C-5), 22.21
(C-8), 20.25 (C-15) and ppm 12.55 (C-16); C22H38O8 (Mw 430.58,
calc.); FAB m/z: 431.1 (MH+, 5 %), 453.1 (MNa+, 11 %).
10Ä-(2-Ethoxyethoxy)-dihydroartemisinin 6a (R = CH2-CH3, n = 1)
Ether 6a was afforded in 35 % yield as clear oil after puri-
fied by flash silica gel column chromatography eluting with
DCM:EtOAc (15:1). ÇH (600 MHz, CDCl3): 5.41 (1H, s, H-12), 4.93
(1H, d, J 4.5 Hz, H-10), 3.95–3.90 (1H, m, OCH-CH2-O, H-18a),
3.62–3.45 (5H, m, H-18b, -19 and H-21), 2.29–2.20 (1H, m, H-8a),
1.99 (1H, dd, J 4.5 and 42.6 Hz, H-9), 1.74–1.67 (1H, m, H-5a),
1.58–1.48 (3H, m, H-22), 1.39–1.33 (5H, m, H-5, -6 and H-8),
1.29–1.2 (4H, m, H-4 and H-7), 1.13–1.0 (3H, m, H-14)
and ppm 0.95–0.89 (6H, m, H-15 and H-16); ÇC (600 MHz, CDCl3):
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Scheme 1
Synthesis of artemisinin-EG ethers.
102.95 (C-10),102.85 (C-3), 88.80 (C-12), 81.46 (C-12a), 69.45
(C-19), 67.51 (C-21), 66.36 (C-18), 51.80 (C-5a), 46.32 (C-8a), 39.45
(C-9), 37.15 (C-4), 36.39 (C-7), 34.45 (C-6), 31.38 (C-14), 25.82 (C-5),
24.58 (C-8), 19.97 (C-15), 19.40 (C-16) and ppm 15.08 (C-22);
C19H32O6 (Mw 356.45, calc.); FAB m/z: 357.4 (MH+, 10 %), 379.3
(MNa+, 7 %).
10~-(2-Ethoxyethoxy)-dihydroartemisinin 6b (R = CH2-CH3, n = 1)
Ether 6b was afforded in 17 % yield as clear oil after puri-
fied by flash silica gel column chromatography eluting with
DCM:EtOAc (15:1). ÇH (600 MHz, CDCl3): 5.27 (1H, s, H-12), 4.45
(1H, d, J 9.3 Hz, H-10), 3.97 (1H, dd, J 10.7, 4.3 Hz, H-18a),
3.60–3.46 (5H, m, H-18b, -19 and H-21), 2.55 (1H, d, J 3.3 Hz,
H-8a), 2.33 (1H, Ç, J 5.7, 9.3 and 28.3 Hz, H-9), 2.00–1.90 (1H, m,
H-5a), 1.85–1.51 (3H, m, H-22), 1.51–1.32 (4H, m, H-4 and H-8),
1.32–1.07 (5H, m, H-5, -6 and H-7) and ppm 1.00–0.75 (9H, m,
H-14, -15 and H-16); ÇC (600 MHz, CDCl3): 104.23 (C-10), 100.35
(C-3), 91.16 (C-12), 80.40 (C-12a), 69.95 (C-19), 68.13 (C-21), 66.48
(C-18), 51.52 (C-5a), 45.34 (C-8a), 37.33 (C-9), 36.28 (C-4), 34.28
(C-7), 32.46 (C-6), 26.00 (C-14), 24.67 (C-5), 22.22 (C-8), 20.25
(C-15), 15.11 (C-16) and ppm 12.40 (C-22); C19H32O6 (Mw 356.45,
calc.); FAB m/z: 357.4 (MH+, 10 %), 379.3 (MNa+, 8 %).
10Ä-[2-(2-Ethoxyethoxy) ethoxy]-dihydroartemisinin 7
(R = CH2-CH3, n = 2)
Ether 7 was obtained as light yellow oil 48 % yield after purifi-
cation on flash silica gel eluting with DCM:EtOAc (10:1),
C21H36O7; ÇH (600 MHz, CDCl3): 5.37 (1H, s, H-12), 4.76 (1H, d,
J 4.6 Hz, H-10), 3.92–3.86 (1H, m, H-18a), 3.62–3.45 (9H, m, H-18b,
-19, -21, -22 and H-24), 2.55 (1H, dd, J 8.6 and 19.4 Hz, H-8a), 1.96
(1H, d, J 14.5 Hz, H-9), 1.77 (1H, dd, J 11.6 and 28.0 Hz, H-5a),
1.70–1.54 (3H, m, H-25), 1.44–1.35 (4H, m, H-4 and H-8), 1.26 (1H,
d, J 5.7 Hz, H-6), 1.16 (4H, dt, J 6.0 and 13.9 Hz, H-5 and H-7)
and ppm 0.90–0.82 (9H, m, H-14, -15 and H-16); ÇC (600 MHz,
CDCl3): 103.90 (C-10), 101.99 (C-3), 87.91 (C-12), 81.14 (C-12a),
70.52 (C-19), 70.27 (C-22), 69.94 (C-21), 67.39 (C-24), 66.65 (C-18),
52.56 (C-5a), 44.57 (C-8a), 37.34 (C-9), 36.41 (C-4), 34.77 (C-7),
30.82 (C-6), 26.17 (C-14), 24.67 (C-5), 24.33 (C-8), 20.24 (C-15),
15.11 (C-16) and ppm 12.97 (C-25); C19H32O6 (Mw 400.51, calc.);
FAB m/z: 401.5 (MH+, 8 %), 426.4 (MNa+, 7 %).
10Ä-{2-[2-(2-ethoxyethoxy)ethoxy]ethoxy}-dihydroartemisinin 8
(R = CH2-CH3, n = 3)
Ether 8 as obtained as clear oil in 51 % yield after purification by
flash silica gel column chromatography eluting with
DCM:EtOAc (5:1). ÇH (600 MHz, CDCl3): 5.35 (1H, s, H-12), 4.75
(1H, d, J 4.4 Hz, H-10), 3.90–3.83 (1H, m, H-18a), 3.60–3.52 (13H,
m, H-18b, -19, -21, -22, -24, -25 and H-27), 2.54 (1H, d, J 3.4 Hz,
H-8a), 1.93(1H, dd, J 4.4 and 13.4 Hz, H-9), 1.73 (1H, Ç, J 8.8, 22.1
and 41.2 Hz, H-5a), 1.54–1.48 (3H, m, H-28), 1.40–1.35 (4H, m, H-4
and H-8), 1.25 (1H, d, J 5.7 Hz, H-6), 1.2 -1.0 (4H, m, H-5 and H-7)
and ppm 0.90–0.82 (9H, m, H-14, -15 and H-16); ÇC (600 MHz,
CDCl3): 104.00 (C-10), 102.06 (C-3), 87.81 (C-12), 81.09 (C-12a),
70.65 (C-19), 70.59 (C-25), 70.55 (C-24), 70. 47 (C-21), 69.78 (C-22),
67.37 (C-27), 66.67 (C-18), 52.62 (C-5a), 44.42 (C-8a), 37.38 (C-9),
36.38 (C-4), 34.66 (C-7), 30.88 (C-6), 26.13 (C-14), 24.64 (C-5), 24.30
(C-8), 20.33 (C-15), 15.15 (C-16) and ppm 12.94 (C-28); C23H40O8
(Mw 444.56, calc.); FAB m/z: 467 (MNa+, 38 %).
2.2.2. Synthesis of Artemisinin-Quinoline Hybrids 16–21
The target hybrids were obtained in a three-step process start-
ing from commercially available dihydroartemisinin and
4,7-dichloroquine.
In the first step, amine-functionalized quinolines 10–15 were
prepared by condensation of various diamines with 4,7-dichloro-
quinoline (Scheme 2) according to a method reported by N’Da
et al.19.
7-Chloro-4-(1,2-diaminoethyl) quinoline 10
Off-white crystals; ÇH (600 MHz, CD3OD): 8.35 (1H, d, J 5.6 Hz,
H-2’), 8.10 (1H, d, J 9.0 Hz, H-5’), 7.76 (1H, d, J 2.1 Hz, H-8’), 7.39
(1H, dd, J 2.1 and 9.0 Hz, H-6’), 6.55 (1H, d, J 5.6 Hz, H-3’), 3.43
(2H, t, J 6.4 Hz, H-3’’) and ppm 2.97 (2H, t, J 6.4 Hz, H-4’’); ÇC
(600 MHz, CD3OD): 152.83 (C-2’), 149.68 (C-4’), 136.34 (C-7’),
127.62 (C-8’), 124.34 (C-5’), 118.82 (C-6’), 98.71 (C-3’), 46.37 (C-3’’)
and ppm 40.88 (C-4’’).
7-Chloro-4-(1,3-diaminopropyl) quinoline 11
Off-white crystals; ÇH (600 MHz, CD3OD): 8.33 (1H, d, J 5.6 Hz,
H-2’), 8.05 (1H, d, J 9.0 Hz, H-5’), 7.75 (1H, d, J 2.0 Hz, H-8’), 7.37
(1H, dd, J 2.1 and 9.0 Hz, H-6’), 6.50 (1H, d, J 5.6 Hz, H-3’), 3.40
(2H, t, J 7.0 Hz, H-3’’), 2.79 (2H, t, J 7.1 Hz, H-5’’) and ppm 1.89
(2H, m, H-4’’); ÇC (600 MHz, CD3OD): 152.68 (C-2’), 149.67 (C-4’),
136.29 (C-7’), 127.61 (C-8’), 125.96 (C-5’), 124.28 (C-6’), 99.65
(C-3’), 41.73 (C-5’’), 40.28 (C-3’’) and ppm 32.03 (C-4’’).
7-Chloro-4-(1,4-diaminophenyl) quinoline 12
Dark brown crystals; ÇH (600 MHz, CD3OD): 8.26 (1H, d, J
5.6 Hz, H-2’), 8.23 (1H, d, J 9.0 Hz, H-5’), 7.80 (1H, d, J 2.1 Hz, H-8’),
7.43 (1H, dd, J 2.1 and 9.0 Hz, H-6’), 7.08 (2H, d, J 8.5 Hz, H-3’’),
6.81 (2H, d, J 8.6 Hz, H-4’’) and ppm 6.58 (1H, d, J 5.6 Hz, H-3’); ÇC
(600 MHz, CD3OD): 151.80 (C-3’’), 150.05 (C-2’), 149.46.10 (C-4),
133.60 (C-6’’), 127.53 (C-7’), 126.37 (C-8’), 124.33 (C- 5’), 124.22
(C-6’), 117.58 (C-5’’), 114.54 (C-4’’) and ppm 100.24 (C-3).
7-Chloro-4-(1,2-diaminopropyl)quinoline 13
Off-white crystals; ÇH (600 MHz, CD3OD): 8.34 (1H, d, J 5.6 Hz,
H-2’), 8.12 (1H, d, J 9.0 Hz, H-5’), 7.76 (1H, d, J 2.0 Hz, H-8’), 7.39
(1H, dd, J 2.0 and ppm 9.0 Hz, H-6’), 6.55 (1H, d, J 5.6 Hz, H-3’),
3.27 (2H, dd, J 5.8 and 7.9 Hz, H-4’’) and ppm 3.25–3.21 (1H, m,
H-3’’), 1.19 (3H, d, J 5.7 Hz, H-6’’); ÇC (600 MHz, CD3OD): 150.62
(C-2’), 148.68 (C-4), 135.21 (C-7’), 128.51 (C-8’), 125.86 (C-5’),
124.38 (C-6), 99.45 (C-3’), 51.77 (C-3’’), 46.49 (C-4’’) and ppm 21.09
(C-6’’).
7-Chloro-4-(piperazin-1-yl) quinoline 14
Off white crystals; ÇH (600 MHz, CD3OD): 8.62 (1H, d, J 5.2 Hz,
H-2’), 8.04 (1H, d, J 9.0 Hz, H-5’), 7.91 (1H, d, J 2.0 Hz, H-8’), 7.50
(1H, dd, J 2.0 and 9.0 Hz, H-6’), 6.99 (1H, d, J 5.2 Hz, H-3’),
3.24–3.20 (4H, m, H-3’’) and ppm 3.12–3.08 (4H, m, H-4’’); ÇC
(600 MHz, CD3OD): 156.88 (C-2’), 152.18 (C-4’), 133.46 (C-7’),
128.03 (C-8’), 126.10 (C-5’), 125.58 (C-6’), 109.22 (C-3’), 54.03
(C-3’’) and ppm 46.40 (C-4’’).
7-Chloro-4-(2-piperazinyl-ethylamino)quinoline 15
Brown white crystals; ÇH (600 MHz, CD3OD): 8.61 (1H, d, J
5.2 Hz, H-2’), 8.01 (1H, d, J 9.0 Hz, H-5’), 7.90 (1H, d, J 2.0 Hz, H-8’),
7.48 (1H, dd, J 2.1 and 9.0 Hz, H-6’), 6.98 (1H, d, J 5.2 Hz, H-3’), 3.27
(4H, s, H-4’’), 2.81 (2H, t, J 6.5 Hz, H-5’’), 2.76 (4H, s, H-3’’)
and ppm 2.57 (2H, t, J 6.5 Hz, H-6’’); ÇC (600 MHz, CD3OD): 151.96
(C-2’), 150.00 (C-4’), 133.41 (C-7’), 127.53 (C-8’), 124.14 (C-5’),
123.91 (C-6’), 98.73 (C-3), 61.30 (C-3’’), 54.16 (C-4’’), 53.08 C-5’’)
and ppm 39.01 (C-6’’).
In the second step, DHA 1 is reacted with bromoethanol in the
presence of boron trifluoride etherate yielding artemisinin
derivative 9 (Scheme 3). Thus, to a solution of dihydro-
artemisinin (10.0 g, 352 mmol) and 2-bromoethanol (9.3 g,
74 mmol) in CH2Cl2 (40 mL), BF3 Et2O (15 drops) was added at
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0 °C. The reaction mixture was stirred at room temperature for
6 h. After the reaction mixture was washed with a saturated
NaHCO3 solution, water and brine, the organic layer was dried
with MgSO4 and evaporated to dryness under reduced pressure.
The residue was recrystallized form petroleum ether to give
9,7 g (71 % yield); of 9 as white crystals20.
10Ä-(2-Bromoethoxy)-dihydroartemisinin 9
Rf = 0.75 (DCM). ÇH (600 MHz, CDCl3): 5.46 (1H, s, H-12), 4.82
(1H, d, J 3.4 Hz, H-10), 4.09 (1H, Ç, J 5.5, 6.6 and 11.8 Hz, H-1’’a),
3.79–3.73 (1H, m, H-1’’b), 3.51–3.47 (2H, m, H-2’’), 2.66–2.59 (1H,
m, H-8a), 2.39–2.30 (1H, dd, J 3.4 and 6.4 H-9), 2.01 (1H, m, H-5a),
1.92–1.81 (m, 2H, H-4), 1.75 (2H, m, H-8), 1.73-1.66 (2H, m, H-7),
1.63-1.48 (1H, m, H-6), 1.41 (3H, s, H-14), 0.93 (3H, d, J 6.4 Hz,
H-16) and ppm 0.91 (3H, d, J 7.4 Hz, H-15); Çc (600 MHz, CDCl3):
104.10 (C-3), 102.02 (C-10), 88.12 (C-12), 81.07 (C-12a), 68.14
(C-1’’), 52.54 (C-5a), 44.33 (C-8a), 37.36 (C-6), 36.37 (C-4), 34.63
(C-7), 31.41 (C-2’’), 30.86 (C-9), 26.12 (C-14), 24.62 (C-5), 24.33
(C-8), 20.34 (C-15) and ppm 12.95 (C-16).
This recation usually leads to a racemate (mixture of ~ and Ä
epimers). However, in this study only the 10Ä-epimer 9 was
isolated20.
Finally, the hybrids 16–21 were obtained by treatment of the
intermediate 9 with the various quinoline based primary/sec-
ondary amines (Scheme 4). For solubility reason, portion of each
free base hybrid was converted into its oxalate salt upon
equimolar reaction between the base and oxalic acid. The
reaction is described as follows: an excess of dry diethylether and
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Scheme 2
Synthesis of amino functionalized quinoline intermediates 10–15.
Scheme 3
Synthesis of 2-(10Ä-dihydroartemisinoxy) ethylbromide 9.
a minimum of methanol were added to 1 equivalent of free base.
Oxalic acid (1 equivalent), dissolved in dry diethylether was
added dropwise to the base solution. The precipitate which
formed subsequently upon stirring at room temperature for
20 mn, was filtered off and dried in vacuo to give the oxalate
salts.
As the 1H NMR data for the oxalate salts were a repetition to
that of the free bases 16–21, only the latters are reported. In the
MS spectra of compounds 16–21, the presence of one chlorine
atom can be deduced by the presence of two peaks in a 3:1 ratio
separated by 2 mass units.
{2-[(7-Chloroquinolin-4-yl)amino]ethyl}(2-{(10Ä-dihydroartemisini
n-10-yl)oxy}ethyl)amine 16
Hybrid 16 was obtained as yellowish oil in 59 % yield; Rf = 0.46
(DCM/MeOH 9:1). ÇH (600 MHz, CDCl3): 8.44 (1H, d, J 5.3 Hz,
H-2’), 7.88 (1H, d, J 1.6 Hz, H-5’), 7.69 (1H, d, J 8.9 Hz, H-8’), 7.28
(1H, dd, J 1.6 and 8.9 Hz, H-6’), 6.32 (1H, d, J 5.3 Hz, H-3’), 5.33
(1H, s, H-12), 4.76 (1H, d, J 3.3 Hz, H-10), 3.92 (1H, dt, J 5.0
and 10.1 Hz, H-1’’a), 3.57–3.45 (m, 1H, H-1’’b), 3.32–3.23 (2H, t,
J 5.6 Hz, H-4’’), 3.00 (2H, t, J 5.6 Hz, H-3’’), 2.87–2.75 (2H, m, H-2’’),
2.58 (1H, dt, J 3.3 and 7.7 Hz, H-9), 1.38 (3H, s, H-14), 0.82 (3H, d,
J 7.4 Hz, H-16) and ppm 0.80 (3H, d, J 5.5 Hz, H-15); ÇC (600 MHz,
CDCl3): 151.79 (C-2’), 149.87 (C-4’), 148.83 (C-8’), 134.74 (C-7’),
128.34 (C-8a), 125.17 (C-6’), 121.39 (C-5’), 117.24 (C-4’), 104.05
(C-3), 102.00 (C-10), 99.01 (C-3’), 87.77 (C-12), 80.84 (C-12a), 67.58
(C-1”), 52.30 (C-5a), 48.55 (C-2”), 47.11 (C-3”), 43.90 (C-8a), 42.00
(C-4”), 37.37 (C-6), 36.23 (C-4), 34.36 (C-7), 30.71 (C-9), 26.05
(C-14), 24.48 (C-5), 24.42 (C-8), 20.15 (C-15) and ppm 12.92 (C-16);




Hybrid 17 was obtained as yellow oil in 35 % yield; Rf = 0.49
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Scheme 4
Synthesis of DHA-quinoline hybrids 16–21 (spacers are directed from DHA to quinoline ring).
(DCM/MeOH 9:1); ÇH (600 MHz, CDCl3): 8.44 (1H, d, J 5.4 Hz,
H-2’), 7.91 (1H, d, J 1.8 Hz, H-5’), 7.70 (1H, d, J 8.9 Hz, H-8’), 7.37
(1H, dd, J 2.0 and 8.9 Hz, H-6’), 6.28 (1H, d, J 5.5 Hz, H-3’), 5.38
(1H, s, H-12), 4.84 (1H, d, J 3.4 Hz, H-10), 4.03 (1H, dt, J 5.2 and
10.4 Hz, H-1a”), 3.60 (1H, dt, J 5.1 and 10.3 Hz, H-1b”), 3.38 (2H, t,
J 5.9 Hz, H-5”), 2.94 (2H, t, J 5.4 Hz, H-3”), 2.87 (2H, t, J 5.2 Hz,
H-2”), 2.68–2.61 (1H, m, H-9), 1.91 (2H, dt, J 5.6 and 11.2 Hz,
H-4”), 1.42 (3H, s, H-14) and ppm 0.87 (6H, dd, J 6.6 and 9.4 Hz,
H-15 and H-16); ÇC (600 MHz, CDCl3): 151.41 (C-2’), 150.73 (C-4’),
148.40 (C-8a’), 135.00 (C-7’), 127.95 (C-8’), 125.25 (C-6’), 121.95
(C-5’), 117.38 (C-4’), 104.22 (C-3), 102.33 (C-10), 98.14 (C-3’), 87.82
(C-12), 80.90 (C-12a), 67.79 (C-1”), 52.41 (C-5a), 49.19 (C-2” and
C-3”), 44.21 (C-8a), 43.88 (C-5”), 37.46 (C-6), 36.32 (C-4), 34.46
(C-7), 30.79 (C-9), 27.11 (C-4”), 26.11 (C-14), 24.62 (C-5), 24.57
(C-8), 20.27 (C-15) and ppm 13.02 (C-16); C29H40ClN3O5 (Mw
546.01, calc.); APCI m/z: 546.34 (M+, 100 %), 548.33.
1-N-(7-Chloroquinolin-4-yl)-4-N-(2-{(10Ä-dihydroartemisinin-
10-yl)oxy}ethyl)benzene-1,4-amine 18
Hybrid 18 was isolated as brownish oil in 35 % yield; Rf = 0.57
(DCM/MeOH 9:1); ÇH (600 MHz, CDCl3): 8.40 (1H, d, J 5.4 Hz,
H-2’), 7.94 (1H, d, J 2.1 Hz, H-5’), 7.85 (1H, d, J 8.9 Hz, H-8’), 7.36
(1H, dd, J 2.1 and 8.9 Hz, H-6’), 7.08 (2H, d, J 8.6 Hz, H-4”), 6.64
(2H, d, J 8.7 Hz, H-5”), 6.57 (1H, d, J 5.4 Hz, H-3’), 5.36 (1H, s,
H-12), 4.81 (1H, d, J 3.4 Hz, H-10), 4.01 (1H, Ç, J 4.1, 6.2 and
10.3 Hz, H-1a”), 3.64 (1H, Ç, J 4.1, 6.5 and 10.4 Hz, H-1b”),
3.38–3.25 (2H, m, H-2”), 2.67–2.59 (1H, m, H-9), 2.34 (1H, td, J 3.9
and 14.1 Hz, H-4a), 2.04–1.96 (1H, m, H-4b), 1.41 (3H, s, H-14),
0.92 (3H, d, J 7.5 Hz, H-16) and ppm 0.91 (3H, d, J 1.8 Hz, H-15); ÇC
(600 MHz, CDCl3): 151.71 (C-2’), 149.65 (C-8’), 149.32 (C-4’),
146.45 (C-4’), 135.02 (C-7’), 128.67 (C-7”), 128.57 (C-8’), 126.64
(C-4’’), 125.51 (C-6’), 121.24 (C-5’), 117.33 (C-4), 113.82 (C-5’’),
104.14 (C-3), 102.19 (C-10), 101.13 (C-3’), 87.87 (C-12), 80.92
(C-12a), 66.95 (C-1”), 52.38 (C-5a), 44.20 (C-8a), 43.85 (C-2”), 37.38
(C-6), 36.30 (C-4), 34.49 (C-7), 30.78 (C-9), 26.09 (C-14), 24.60 (C-5),
24.53 (C-8), 20.27 (C-15) and ppm 13.00 (C-16); C36H38ClN3O5
(Mw 580.11, calc.); APCI m/z: 580.36 (M
+, 100 %), 582.37.
{1-[(7-Chloroquinolin-4-yl)amino]propan-2-yl}(2-{(10Ä-dihydroarte
misinin-10-yl)oxy}ethyl)amine 19
Compound 19 was racemate (mixture 3’’R and 3’’S isomers)
isolated as fluffy light brown crystals in 45 % yield; Mp: 67 °C; ÇH
(600 MHz, CDCl3): 8.47 (2H, d, J 4.7 Hz, H-2’), 7.93–7.88 (m, 2H,
H-5’), 7.71–7.66 (2H, m, H-8’), 7.33 (2H, dd, J 2.1 and 8.9 Hz, H-6’),
6.41–6.38 (1H, m, H-3’), 6.35–6.31 (1H, m, H-3’), 5.99 (s, 1H, H-6”),
5.75 (dd, J = 36.6, 5.9 Hz, 1H, H-6”), 5.37–5.33 (1H, m, H-12), 5.29
(1H, s, H-12), 4.78 (1H, dd, J 4.1 and 7.4 Hz, H-10), 4.76 (1H, d,
J 3.4 Hz, H-10), 3.96 (1H, Ç, J 3.8, 7.1 and 10.3 Hz, H-1’’a), 3.90 (1H,
Ç, J 4.3, 6.4 and 10.5 Hz, H-1’’a), 3.78 (1H, dt, J 5.8 and 11.8 Hz,
H-3”), 3.73 (1H, dt, J 5.6 and 11.6 Hz, H-4”), 3.57–3.51 (1H, m,
H-1’’b), 3.48 (1H, Ç, J 3.8, 6.6 and 10.2 Hz, H-1’’b), 3.30 (1H, t,
J 15.4 Hz, H-4’’a), 3.10 (1H, tt, J 6.4 and 12.9 Hz, H-3”), 3.05–2.96
(1H, m, H-4’’b), 2.96–2.75 (4H, m, H-2”), 1.40 (s, 3H, H-14), 1.38 (s,
3H, H-14), 1.27 (3H, dd, J 4.0 and 6.3 Hz, H-6”), 1.20 (1H, dd, J 3.5
and 6.3 Hz, H- 6”), 0.84–0.80 (6H, m, H-16) and ppm 0.79 (6H, dd,
J 2.8 and 6.8 Hz, H-15); Çc (600 MHz, CDCl3): 151.90 (C-2’), 151.85
(C-2’), 149.99 (C-4’), 149.22 (C-4’), 149.15 (C-8’a), 148.93 (C-8’),
134.82 (C-7’), 128.58 (C-8’), 128.51 (C-8’), 125.32 (C-6’), 125.24
(C-6’), 121.32 (C-5’), 121.25 (C-5’), 117.49 (C-4’a), 117.34 (C-4’a),
104.11 (C-3), 104.07 (C-3), 102.04 (C-3’), 101.80 (C-3’), 99.32 (C-10),
99.11 (C-10), 87.84 (C-12), 87.75 (C-10), 80.90 (C-12a), 80.84
(C-12a), 67.80 (C-1”), 67.57 (C-1”), 54.12 (C-4”), 53.95 (C-4”), 52.33
(C-5a), 51.30 (C-5a), 49.28 (C-2”), 49.23 (C-2”), 47.59 (C-5”), 47.43
(C-5”), 44.18 (C-8a), 44.15 (C-8a), 37.43 (C-6), 37.41 (C-6), 36.29
(C-4), 36.27 (C-4), 34.40 (C-7), 30.72 (C-9), 26.11 (C-14), 24.54 (C-5),
24.50 (C-5), 24.42 (C-8), 24.39 (C-8), 20.19 (C-15), 19.18 (C-15),
18.06 (C-6’’), 17.95 (C-6’’), 12.99 (C-16) and ppm 12.90 (C-16);





Hybrid 20 was obtained as fluffy light yellow crystals in 39 %
yield; Mp: 77 °C; Rf = 0.72 (DCM/MeOH 9:1); ÇH (600 MHz,
CDCl3): 8.69 (1H, d, J 4.9 Hz, H-2’), 8.01 (1H, d, J 1.8 Hz, H-5’), 7.91
(1H, d, J 8.9 Hz, H-8’), 7.39 (1H, dd, J 1.8 and 9.0 Hz, H-6’), 6.80
(1H, d, J 5.0 Hz, H-3’), 5.47 (s, 1H, H-12), 4.82 (1H, d, J 3.3 Hz,
H-10), 4.02–3.95 (m, 1H, H-1’’a), 3.62–3.55 (m, 1H, H-1”b),
3.24–3.14 (4H, m, H-3”), 2.73 (4H, dd, J 6.8 and 12.5 Hz, H-4”),
2.71–2.65 (2H, m, H-2”), 2.65–2.58 (1H, m, H-9), 2.34 (1H, td, J 3.8
and 14.0 Hz, H-4a), 2.04–1.97 (1H, m, H-4b), 1.41 (3H, s, H-14),
0.93 (3H, d, J 6.4 Hz, H-16), 0.90 (3H, d, J 7.4 Hz, H-15); Çc
(600 MHz, CDCl3): 157.00 (C-2’), 151.91 (C-4’), 134.84 (C-7’),
128.82 (C-8’), 126.09 (C-6’), 125.18 (C-5’), 108.89 (C-3’), 104.06
(C-3), 102.02 (C-10), 87.93 (C-12), 81.09 (C-12a), 65.83 (C-1”), 57.86
(C-2”), 53.28 (C-3”), 52.52 (C-5a), 52.26 (C-4”), 44.38 (C-8a), 37.54
(C-6), 36.37 (C-4), 34.65 (C-7), 30.83 (C-9), 26.17 (C-14), 24.72 (C-5),
24.40 (C-8), 20.33 (C-15) and ppm 13.07 (C-16); C30H40ClN3O5
(Mw 558.11, calc.); APCI m/z: 558.43 (M
+, 100 %), 560.25.
7-Chloro-N-{2-[4-(2-{10Ä-dihydroartemisinin-10-yl]oxy}ethyl)piper
azin-1-yl]ethyl}quinolin-4-amine 20
Hybrid 21 was obtained as dark yellow oil in 52 % yield; Rf =
0.51 (DCM/MeOH 9:1); ÇH (600 MHz, CDCl3): 8.61 (1H, d, J 5.0 Hz,
H-2’), 7.94 (1H, d, J 1.9 Hz, H-5’), 7.84 (1H, d, J 9.0 Hz, H-8’), 7.32
(1H, dd, J 2.0 and 9.0 Hz, H-6’), 6.72 (1H, d, J 5.0 Hz, H-3’), 5.33
(1H, s, H-12), 4.75 (1H, d, J 3.0 Hz, H-10), 3.90 (1H, dt, J 4.8 and
9.9 Hz, H-1’’a), 3.48 (1H, td, J 5.3 and 10.8 Hz, H-1’’b), 3.13 (4H, s,
H-3”), 2.76 (2H, t, J 5.1 Hz, H-2”), 2.72 (2H, t, J 5.9 Hz, H-5”), 2.66
(4H, s, H-4”), 2.56 (3H, t, J 5.8 Hz, H-6” and H-9), 2.27 (1H, td, J 3.8
and 14.4 Hz, H-4a), 1.94 (1H, d, J 14.5 Hz, H-4b), 1.34 (3H, s, H-14),
0.85 (3H, s, H-16) and ppm 0.84 (3H, s, H-15); ÇC (600 MHz,
CDCl3): 156.77 (C-2’), 151.70 (C-4’), 149.87 (C-8’), 134.69 (C-7’),
125.92 (C-6’), 125.06 (C-5’), 121.69 (C-4a), 108.68 (C-3’), 103.92
(C-3), 101.92 (C-10), 87.68 (C-12), 80.80 (C-12a), 67.59 (C-1”), 57.65
(C-2”), 52.96 (C-3”), 52.30 (C-5a), 52.00 (C-4”), 49.16 (C-5”), 46.05
(C-6”), 44.12 (C-8a), 37.23 (C-6), 36.19 (C-4), 34.43 (C-7), 30.67
(C-9), 25.99 (C-14), 24.48 (C-5), 24.38 (C-8), 20.17 (C-15)
and ppm 13.01 (C-16); C32H45ClN4O5 (Mw 601.18, calc.); APCI m/z:
601.25 (M+, 100 %), 603.31.
2.3. In vitro Antimalarial Activity
The derivatives were tested in triplicate against the D10 and
Dd2 strains of Plasmodium falciparum. Continuous in vitro cultures
of asexual erythrocyte stages of P. falciparum were maintained
using a modified method reported by Trager and Jensen21.
Quantitative assessment of antiplasmodial activity in vitro was
determined via the parasite lactate dehydrogenase assay using a
modified method described by Makler22.
The test samples were prepared as a 2 mg mL–1 stock solution
in 10 % dimethyl sulfoxide (DMSO) and sonicated to enhance
solubility. Stock solutions were stored at –20 °C. Further dilu-
tions were prepared on the day of the experiment. Chloroquine
Ä-artemether and dihydroartemisinin were used as the reference
drugs in all experiments. A full-dose response was performed
for all compounds to determine the concentration inhibiting
50 % of parasite growth (IC50).
For a range starting from 100 ng mL–1 the following was ap-
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plied: The starting concentration of 100 ng mL–1 was serially di-
luted, 2-fold in complete medium to give ten dilutions with the
lowest concentration being 0.2 ng mL–1 . Thus the concentrations
considered were 100 ng mL–1 , 50 ng mL–1 , 25 ng mL–1 , 12.5 ng
mL–1 , 6.25 ng mL–1 , 3.125 ng mL–1 , 1.56 ng mL–1 , 0.78 ng mL–1 ,
0.39 ng mL–1 and 0.195 ng mL–1 . The same dilution technique
was used for all samples. The samples are tested in triplicate. The
solvents to which the parasites were exposed to had no measur-
able effect on the parasite viability. The ethers and the hybrids
were tested in the same experimental conditions but at different
dates. The IC50-values were obtained using a non-linear
dose-response curve fitting analysis via Graph Pad Prism v.4.0
software, and the values on molar basis in Table 2 were obtained
by dividing those on mass basis by the molecular weight of each
compound.
3. Results and Discussion
3.1. Chemistry
3.1.1. Artemisinin–EG Ethers
The new ether derivatives of artemisinin 3–5b and 6a–8 were
prepared by treatment of DHA with an appropriate MEG or
EEG, respectively, in the presence of boron trifluoride diethyl
etherate (BF3.Et2O) at room temperature, and were obtained
with yields in the 7–51 % range. The purification was achieved
by flash column chromatography on silica gel. An oxonium ion
at position 11 has been suggested to be involved in the ether
formation7. In some cases a mixture of two isomers (5a and 5b,
and 6a and 6b) was formed and they were successfully separated.
The configuration at the C-10 position of the ethers was assigned
based on the vicinal coupling constant JH-9:H-10
23.
A large coupling constant between H-9 and H-10 in the case of
the 10~-isomer, JH-9:H-10 = 9–10 Hz
9, indicates the relative trans
configuration. The 10Ä-isomer, on the other hand has a small
coupling constant, JH-9:H-10 = 3.6–5 Hz
8. The relative configuration
for such a compound is cis. Thus, compounds 3, 4, 5a, 6a, 7 and 8,
all with JH-9:H-10 values in the 4–5 Hz range were 10Ä-isomers. On
contrary, compounds 5b (JH-9:H-10 = 9.2 Hz) and 6b (JH-9:H-10 =
9.3 Hz) were the 10~-epimers of 5b and 6b, respectively (Table 1).
In 1H NMR spectra of these, the signals of H-12, H-10 and OCH2
appear up field whereas those of the 10Ä-epimers all appear
downfield23. Thus, in correlation with the yields, one can con-
clude that the experimental conditions favoured the formation
of 10Ä-epimers in majority.
In the 1H NMR spectrum of DHA, the signals of H-12 and H-10
for the 10Ä-epimer appeared at ÇH 5.41 (s) and 4.8 (s), respectively,
whereas for the 10~-epimer they appeared at ÇH 5.33 (s) and 4.43
(s), respectively.
The 13C NMR spectrum of DHA showed signals at 104.99, 99.40,
88.62, 81,42, 52.87, 45.51, 37.65, 36.84, 34.61, 32.28, 25.60, 22.99,
22.72, 20.00 and 14.87 ppm corresponding to C-10, C-3, C-12,
C-12a, C-5a, C-8a, C-9, C-4, C-7, C-6, C-14, C-5, C-8, C-15 and
C-16, respectively. These signals were all present in the spectra of
the ethers, confirming the presence of the DHA moiety in these
compounds.
The chemical structures of the title compounds 3–8 were
confirmed by NMR and FAB-MS data. The 1H NMR spectra of
compounds 3–5b exhibited resonances in the 3.99–3.31 ppm region
characteristic of methylene hydrogen of OCH2-CH2O belonging
to MEG chain while the signal of OCH3 hydrogen appeared as
singlet in 3.37–3.31 ppm region. The 1H spectra of ethers 6a–8
showed a signal in 3.97–3.45 ppm region characteristic of methy-
lene hydrogen OCH2-CH2O belonging to EEG chain and the
presence of CH3 of ethyl hydrogen is confirmed by the signal
between 1.25–1.00 ppm. The presence of the MEG chain in the
structures of 3–5b was further confirmed by the resonance of the
methoxy (OCH3) carbon between 58.77 and 59.03 ppm, and
OCH2-CH2O carbons between 71.64–67.53 ppm in
13C spectra. In
the structures of compounds 6a–8, the presence of EEG chain
was confirmed by the resonance of CH3 of ethyl moiety between
15.08–12.40 while those of OCH2-CH2O resonated between
70.86–66.36 ppm in the 13C NMR spectra. Furthermore, due to
the close proximity to several asymmetric carbon centers on
the DHA moiety, the methylene hydrogen on the carbon ~
adjacent to the new ether oxygen are non-equivalent and thus
appear as an AB quartet24.
3.1.2. Artemisinin–Quinoline Hybrids
The hybrids were obtained in yields varying from 35 to 59 %
and their structure confirmed by NMR and MS spectroscopy.
Only two hybrids viz. 19 and 20 were solids, all others were
either yellowish or brownish oils. Part of free bases hybrids 16–19
and 21 were treated with oxalic acid to obtain the oxalate
salts 16a–19a, and 21a, primarily for solubility and stability
reasons. DHA was supplied as a mixture of epimers, but only
Ä-epimerr of 2-(10-dihydroartemisinoxy)ethylbromide 9 was
obtained, therefore all synthesized hybrids were Äepimers and
were tested as such alongside the oxalate salts.
Here again, due to the close proximity to several asymmetric
carbon centers on the DHA moiety, the methylene hydrogen on
the carbon ~ adjacent to the new ether oxygen in the structure of
9, and therefore in those of hybrids 16–21, are non-equivalent
and thus appear as an AB quartet 23.
Furthermore, only the relevant peaks for hybrids 16–21 were
notated, and as the NMR data for the oxalate salts were a repeti-
tion of those of the free bases, only the latter are reported. Thus,
the peaks of H-12, H-10 as well as those H-18a,b and H-19,
protons of ~ and Ä methylene carbon adjacent to O-17 of DHA
are noticeable in the 1H spectra of all hybrids. In the MS spectra of
the hybrids, the presence of one chlorine atom can be deduced
by the presence of two peaks in a 3:1 ratio separated by 2 mass
units.
3.2. In vitro Antimalarial Activity
3.2.1. Artemisinin–EG Ethers
The new EG oligomeric ethers of artemisinin were tested in
vitro against both the CQS and CQR strains of Plasmodium
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Table 1 Configurational information of compounds 3–8 and 16–21.
Compound JH-9:H-10 /Hz Epimer Configuration C-10
1 Ä cis
3 4.8 Ä ”
4 4.5 Ä ”
5a 4.3 Ä ”
5b 9.2 ~ trans
6a 4.5 Ä cis
6b 9.3 ~ trans
7 4.6 Ä cis
8 4.4 Ä ”
16 3.4 Ä cis
17 3.4 Ä ”
18 3.4 Ä ”
19 3.3; 4.1 Ä ”
20 3.3 Ä ”
21 3.0 Ä ”
falciparum. All tested ethers were active against both the D10 and
Dd2 strains. However, they were more active against the
Dd2 strain, and showed comparable activity against the
D10 strain as can be seen from their resistance index (RI) values
in the 0.5 to 0.9 range (Table 2).
Ethers 3, 5a and 6a were found less potent than ARM against
either the D10 or Dd2 strain, while 5b, 6b and 7 showed less
potency than ARM only against D10 strain. With the exception of
compound 3 which was remarkably less potent than CQ against
the parasites of the D10 strain [IC50 values; 0.245 vs. 0.06 nM], all
other ethers showed potency similar to that of CQ against the
same strain.
The activity against the CQ resistant strain revealed a picture
slightly different from that against the sensitive strain. Indeed,
all the ethers were active against the Dd2 strain. They were all
less potent than ARM. However, compound 3 possessed potency
similar to that of CQ (IC50 values; 0.51 nM vs. 0.47 nM), while all
others were more potent than CQ.
In summary, compound 3 was distinctively the least active of
all synthesized ethers irrespective of the strain while ether 8 was
the most active. With activity comparable to that of ARM against
both strains, and potency higher than that of CQ, the com-
pound 8 lends itself as a good drug candidate to undergo
pharmacokinetic studies to ascertain whether or not through
that ether the half-life of artemisinin has been enhanced.
3.2.2. Artemisinin–Quinoline Hybrids
Two reference antimalarial drugs, viz. CQ and DHA, were
tested alongside the hybrids and their salts. The results showed
that compounds 16a, 17a, 18 and 18a, 19 and 19a, 20, and 21a
displayed a good antimalarial activity profile as they had po-
tency comparable to that of CQ against the D10 strain, and were
found more active than CQ against the Dd2 strain. However,
16a, 17a, 19 and 19a, and 21a were more active against the
Dd2 strain–indicated by the the resistance index RI ¡ 1.5. Hybrid
19 and its oxalate 19a displayed the best activity profile against
both strains. Compounds 16, 17 and 21 showed poor activity
against the CQS strain, which was also seen against the
CQR one.
Overall the oxalates had better antiplasmodial activity than
their free base hybrids, presumably due to their better solubility
in the testing aqueous medium. The good activity of some of
these compounds against the Dd2 strain is in agreement with the
results from previous studies25,26. All the synthesized compounds
were less active than DHA irrespective of the strain. This a major
setback as one of the objectives of the study was the search for
more potent antimalarials in comparison with the current
artemisinins.
4. Conclusion
We have successfully synthesized series of ethylene glycol
ethers and quinoline hybrids of artemisinin through derivati-
zation at its 10-OH position. The in vitro antimalarial activity
indicates that all the compounds were active against both D10
and Dd2 strains of Plasmodium falciparum. However, none of the
compounds showed remarkably better activity than either
artemether or dihydroartemisinin irrespective of the strain.
The majority of ethers showed higher potency than CQ
against Dd2 strain. The artemisinin derivative 8 featuring 3 EO
units and an ethyl side chain terminal group was the most active
of all among the ethers. Hybrid 19 containing isopropyl linker on
the other hand and its oxalate salt 19a possessed the highest
antimalarial activities, among the hybrids, and were indeed
more potent than CQ against Dd2 strain.
Thus, ether 8, and the hybrids 19 and 19a lend themselves
as good drug candidates to undergo further studies, namely
pharmacokinetics, to ascertain whether or not the half-life of
artemisinin has been increased through these compounds as
one objective of this project was the search for long acting
artemisinin derivatives.
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Table 2 In vitro antiplasmodial activity of synthesized artemisinin-PEG ethers and -quinoline hybrids
Compound n D10: IC50 /nM S.D. Dd2: IC50 /nM S.D. RI
3 2 0.245 0.049 0.510 0.007 2
4 3 0.045 0.002 0.039 0.001 0.9
5a 3 0.094 0.005 0.061 0.002 0.7
5b 3 0.051 0.006 0.030 0.002 0.6
6a 3 0.090 0.003 0.083 0.013 0.9
6b 3 0.051 0.007 0.025 0.002 0.5
7 3 0.051 0.005 0.032 0.004 0.6
8 3 0.030 0.003 0.023 0.001 0.8
Ä-ARM 3 0.021 0.008 0.004 0.000 0.4
CQ b 3 0.060 0.004 0.473 0.013 7
16 3 0.084 0.022 0.153 0.002 1.8
16a 3 0.021 0.001 0.025 0.001 1.2
17 3 0.117 0.016 0.184 0.005 1.6
17a 3 0.014 0.003 0.020 0.001 1.4
18 3 0.030 0.003 0.069 0.002 2.3
18a 3 0.017 0.003 0.030 0.012 1.8
19 * 3 0.007 0.001 0.009 0.001 1.3
19a 3 0.008 0.001 0.011 0.002 1.4
20 * 3 0.034 0.002 0.075 0.005 2.2
21 * 3 0.218 0.022 0.300 0.076 1.4
21a 3 0.031 0.003 0.032 0.004 1
DHA 4 0.005 0.001 0.002 0.000 0.4
CQ 3 0.035 0.011 0.255 0.085 7.3
*Tested as a suspension. n = Number of data sets averaged. Resistance index (RI) = IC50 Dd2/IC50 D10. S.D. = standard deviation.
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